[18F]Fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma

Clinical Lymphoma and Myeloma

Volumn 8, Issue 3, 2008, Pages 159-165

  Gill, Saar ^a   Wolf, Max ^a   Prince, H Miles ^a,b   Januszewicz, Henry ^a   Ritchie, David ^a,b   Hicks, Rodney J ^a,b   Seymour, John F ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

False negative results; Gastrointestinal involvement; Nodal disease; Terminal ileum

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; RITUXIMAB; VINCRISTINE; RADIOPHARMACEUTICAL AGENT;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SCINTISCANNING; CANCER STAGING; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GASTRITIS; GASTROINTESTINAL DISEASE; HUMAN; MALE; MANTLE CELL LYMPHOMA; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; STOMACH LESION; TREATMENT RESPONSE; METHODOLOGY; MIDDLE AGED; MONITORING; RECURRENT DISEASE; RETROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 49649088421     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.019     Document Type: Article

References (23)

1. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007; 25:571-8.
2. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of wholebody 2-deoxy-2-(F-18)fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203:795-800.
3. Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose for the staging of low-grade non-Hodgkin's lymphoma. Ann Oncol 2001; 12:825-30.
4. Blum RH, Seymour, JF, Wirth A, et al. Frequent impact of 18F-fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 2003; 4:43-9.
5. Hicks RJ, MacManus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005; 35:165-75.
6. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of 18Ffluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67-Gallium scintigraphy in the evaluation of lymphoma. Cancer 2007; 110:652-9.
7. Hicks RJ. The evolving role of fluorodeoxyglucose positron emission tomography (FDG PET) in lymphoma: how do we reconcile conflicting results in the era of evidence-based medicine? Leuk Lymphoma 2006; 47:2008-10.
8. Jaffe ES, Harris NL, Stein H, et al (eds). WHO classification of tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
9. Leitch HA, Gascoyne RD, Chhanabhai M, et al. Limited-stage mantle-cell lymphoma. Ann Oncol 2003; 14:1555-61.
10. McLaughlin P, Seymour J, Fuller L, et al. Combined modality therapy for stage I-II MALT lymphoma and mantle cell lymphoma. Ann Oncol 1996; 7:211-3.
11. Romaguera JE, Medeiros LJ, Hagemeister FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003; 97:586-91.
12. Kostakoglu L, Leonard JP, Kuji I, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94:879-88.
13. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002; 112:262-8.
14. Waxman AD, Eller D, Ashook G, et al. Comparison of gallium-67 and thallium-201 scintigraphy in peripheral and intrathoracic lymphoma. J Nucl Med 1996; 37:46-50.
15. Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol 2005; 23:4577-80.
16. Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 1997; 61:1023-7.
17. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group. J Clin Oncol 1999; 17:1244-53.
18. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography with fluorine-18 fluorodeoxyglucose after first line chemotherapy in non-Hodgkin's lymphoma: is 18F-FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19:414-9.
19. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429-33.
20. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-86.
21. Pakos EE, Fotopoulos AD, Ioannidis PA. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: A meta-analysis. J Nucl Med 2005; 46:958-63.
22. Kumar R, Xiu Y, Potenta S, et al. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med 2004; 45:1796-803.
23. Schoder H, Noy A, Gonen M, et al. Intensity of 18Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:4643-51.